We are live on ! Find out more
ARNA

Arena Pharmaceuticals Inc

Delisted

ARNA was delisted on the 10th of March, 2022.

121 hedge funds and large institutions have $451M invested in Arena Pharmaceuticals Inc in 2014 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 34 increasing their positions, 39 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% less funds holding

Funds holding: 129121 (-8)

13% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 39

28% less capital invested

Capital invested by funds: $628M → $451M (-$177M)

33% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 21

50% less call options, than puts

Call options by funds: $12.7M | Put options by funds: $25.4M

Holders
121
Holders Change
-8
Holders Change %
-6.2%
% of All Funds
3.51%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
14
Increased
34
Reduced
39
Closed
21
Calls
$12.7M
Puts
$25.4M
Net Calls
-$12.6M
Net Calls Change
+$7.61M
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$124M +$7.74M +173,457 +6%
Vanguard Group
2
Vanguard Group
Pennsylvania
$55.3M -$614K -13,759 -1%
State Street
3
State Street
Massachusetts
$31.7M +$4.13M +92,602 +14%
BFA
4
BlackRock Fund Advisors
California
$31.3M -$1.2M -26,902 -3%
O
5
OppenheimerFunds
New York
$29.3M
BIT
6
BlackRock Institutional Trust
California
$25.4M -$222K -4,974 -0.8%
DM
7
Deerfield Management
New York
$24.5M +$6.6M +147,893 +34%
Susquehanna International Group
8
Susquehanna International Group
Pennsylvania
$16.5M -$578K -12,954 -3%
Invesco
9
Invesco
Georgia
$11.2M +$5.24M +117,329 +78%
Northern Trust
10
Northern Trust
Illinois
$10.7M -$94.8K -2,123 -0.8%
Norges Bank
11
Norges Bank
Norway
$8.09M -$8.62M -193,078 -50%
Group One Trading
12
Group One Trading
Illinois
$6.47M +$3.3M +73,994 +92%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$5.25M -$42.7K -957 -0.8%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$5.14M -$127K -2,836 -2%
TCIM
15
TIAA CREF Investment Management
New York
$5.12M +$493K +11,033 +10%
TA
16
Teachers Advisors
New York
$3.76M
Renaissance Technologies
17
Renaissance Technologies
New York
$3.24M +$3.2M +71,580 +1,248%
GC
18
Guggenheim Capital
Illinois
$3.21M +$526K +11,789 +18%
California Public Employees Retirement System
19
California Public Employees Retirement System
California
$2.67M
BIM
20
BlackRock Investment Management
Delaware
$2.53M +$15.5K +347 +0.6%
Deutsche Bank
21
Deutsche Bank
Germany
$2.52M -$184K -4,131 -6%
Charles Schwab
22
Charles Schwab
California
$2.26M -$1.85M -41,340 -43%
AIG
23
American International Group
New York
$2.18M -$58K -1,300 -2%
SFM
24
Sphera Funds Management
Israel
$2.1M +$2.23M +50,000 New
AllianceBernstein
25
AllianceBernstein
Tennessee
$1.96M

ARNA Hedge Fund Activity: Q3 2014 in Review

121 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Arena Pharmaceuticals Inc (ARNA) for Q3 2014, worth a combined $451M — down 28% from $628M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of ARNA and 14 opened new positions — a net loss of 7 holders — while 39 trimmed existing stakes and 34 added.

The largest buyer was Wellington Management Group, adding an estimated $7.74M. The largest seller was Morgan Stanley, cutting an estimated $9.76M.

  • 121 institutional investors held Arena Pharmaceuticals Inc (ARNA) as of Q3 2014, down from 129 in Q2 2014.
  • Funds reported $451M of Arena Pharmaceuticals Inc stock for Q3 2014, down 28% quarter-over-quarter.
  • 14 funds opened new Arena Pharmaceuticals Inc positions in Q3 2014 and 21 closed out, a net change of -7 holders.
  • The largest Arena Pharmaceuticals Inc buyer in Q3 2014 was Wellington Management Group, an estimated $7.74M added.
  • The largest Arena Pharmaceuticals Inc seller in Q3 2014 was Morgan Stanley, an estimated $9.76M sold.

Based on aggregated 13F filings for Q3 2014.